Mineralocorticoid Receptor Antagonists and the Metabolic Syndrome
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Key components of the metabolic syndrome (MetS), ie, obesity and insulin resistance, are associated with increased aldosterone production and mineralocorticoid receptor (MR) activation. Both MetS and hyperaldosteronism are proinflammatory and pro-oxidative states associated with cardiovascular disease. This review discusses emerging data that MR activation may contribute to abnormalities seen in MetS. In view of these data, MR antagonists may be beneficial in MetS, not only by controlling hypertension but also by reversing inflammation, oxidative stress, and defective insulin signaling at the cellular-molecular level. Clinical trials have demonstrated benefits of MR antagonists in heart failure, hypertension, and diabetic nephropathy, but additional trials are needed to demonstrate the clinical significance of MR blockade in MetS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Effect of valsartan on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001121 · Cited by 660
Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L., & Toto, R. D. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009070737 · Cited by 388
Guo, C., Ricchiuti, V., Lian, B. Q., Yao, T. M., Coutinho, P., Romero, J. R., Li, J., Williams, G. H., & Adler, G. K. (2008) · Circulation · doi:10.1161/circulationaha.107.748640 · Cited by 342
Self-citationPivotal role of the mineralocorticoid receptor in corticosteroid‐induced adipogenesis
Caprio, M., Fève, B., Claës, A., Viengchareun, S., Lombès, M., & Zennaro, M.-C. (2007) · The FASEB Journal · doi:10.1096/fj.06-7970com · Cited by 337
The renin-angiotensin-aldosterone system, glucose metabolism and diabetes
Giacchetti, G., Sechi, L. A., Rilli, S., & Carey, R. M. (2005) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2005.02.003 · Cited by 267
Wada, T., Kenmochi, H., Miyashita, Y., Sasaki, M., Ojima, M., Sasahara, M., Koya, D., Tsuneki, H., & Sasaoka, T. (2010) · Endocrinology · doi:10.1210/en.2009-0869 · Cited by 189
Adiponectin and Insulin Sensitivity in Primary Aldosteronism
FALLO, F., DELLAMEA, P., SONINO, N., BERTELLO, C., ERMANI, M., VETTOR, R., VEGLIO, F., & MULATERO, P. (2007) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2007.03.012 · Cited by 101
Effect of adrenal steroids on insulin release from cultured rat islets of Langerhans
Pierluissi, J., Navas, F. O., & Ashcroft, S. J. H. (1986) · Diabetologia · doi:10.1007/bf00456122 · Cited by 66 · cited 1×
“Hyperaldosteronism is associated with impaired carbohydrate metabolism, attributed for many years mainly to altered insulin release from the pancreatic beta cells owing to hypokalemia, fibrosis, or a direct inhibitory effect of corticosteroid on the beta cells [26, 27 ].”
BackgroundImpact of excess aldosterone on glucose homeostasis in adult male rat
Selvaraj, J., Muthusamy, T., Srinivasan, C., & Balasubramanian, K. (2009) · Clinica Chimica Acta · doi:10.1016/j.cca.2009.06.030 · Cited by 38 · cited 2×
“Aldosterone administration to rats resulted in decreased skeletal muscle expression and translocation to the plasma membrane of the insulin responsive glucose transporter, GLUT4 [ 36 ].”
Background
Cited by
Metabolic syndrome: definitions and controversies
Kassi, E., Pervanidou, P., Kaltsas, G., & Chrousos, G. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-48 · Cited by 1,565
“Furthermore, either use of angiotensin II type 1 receptor antagonists or genetic knockout of angiotensin II type 1 receptor are known to effectively attenuate lipid accumulation in the liver [99-105].”
Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy
Jia, G., DeMarco, V. G., & Sowers, J. R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.216 · Cited by 949
Briones, A. M., Nguyen Dinh Cat, A., Callera, G. E., Yogi, A., Burger, D., He, Y., Corrêa, J. W., Gagnon, A. M., Gomez-Sanchez, C. E., Gomez-Sanchez, E. P., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.190223 · Cited by 375
The multifaceted mineralocorticoid receptor
Gomez‐Sanchez, E., & Gomez‐Sanchez, C. E. (2014) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2014.tb00569.x · Cited by 55
Selvaraj, J., Sathish, S., Mayilvanan, C., & Balasubramanian, K. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1452-2 · Cited by 47
Metadata
- Authors
- Tirosh, A., Garg, R., & Adler, G. K.
- Venue
- Current Hypertension Reports
- Published
- 2010-06-19
- Volume
- 12
- Issue
- 4
- Pages
- 252-257
- ISSN
- 1522-6417 (ISSN-L)
- 1534-3111
- OpenAlex
- W2023943642
- Cited by
- 71
- References
- 10
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mineralocorticoid Receptor Antagonists and the Metabolic Syndrome. https://app.cochat.ai/papers/10.1007/s11906-010-0126-2
- The paper
- Tirosh, A., Garg, R., & Adler, G. K. (2010). Mineralocorticoid Receptor Antagonists and the Metabolic Syndrome. Current Hypertension Reports. https://doi.org/10.1007/s11906-010-0126-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.